Table 1.
Patient, tumor, and treatment characteristics
| Characteristics | 3D-CRT (n = 28) | IMRT (n = 20) | P |
|---|---|---|---|
| Patient | |||
| Median age, y (range) | 61.5 (26.4–87.9) | 57.0 (39.3–86.1) | 0.594 |
| Gender, n (%) | 0.493 | ||
| Male | 14 (50.0) | 12 (60.0) | |
| Female | 14 (50.0) | 8 (40.0) | |
| Race, n (%) | 1 | ||
| White | 13 (46.4) | 10 (50.0) | |
| Black | 9 (32.1) | 7 (35%) | |
| Hispanic | 5 (17.9) | 3 (15.0) | |
| Other | 1 (3.6) | 0 (0.0) | |
| Tumor and disease | |||
| Clinical stage (AJCC 2010), n (%) | 0.675 | ||
| I | 1 (3.6) | 1 (5.0) | |
| II | 12 (42.9) | 10 (50.0) | |
| III | 10 (35.7) | 8 (40.0) | |
| Iva | 5 (17.9) | 1 (5.0) | |
| Median tumor size, cm (range)a | 4.2 (1.0–15.0) | 3.0 (1.1–10.0) | 0.059 |
| Tumor grade, n (%)a | 0.165 | ||
| G1 | 1 (3.7) | 0 (0.0) | |
| G2 | 22 (81.5) | 13 (65.0) | |
| G3 | 4 (14.8) | 7 (35.0) | |
| Treatment | |||
| Concurrent chemotherapy, n (%) | 0.679 | ||
| 5-FU | 18 (64.3) | 14 (70.0) | |
| Capecitabine | 10 (35.7) | 6 (30.0) | |
| Type of surgery, n (%) | 0.805 | ||
| None | 10 (35.7) | 6 (30.0) | |
| Lower anterior resection | 10 (35.7) | 6 (30.0) | |
| Abdominoperineal resection | 6 (21.4) | 5 (25.0) | |
| Median RT dose, Gy (range) | 50.4 (30.6–50.4) | 50.0 (45.0–50.4) | <.0001 |
| Treatment duration, d, median (range) | 39 (23–52) | 35 (32–42) | <.0001 |
| Local excision, n (%) | 2 (7.1) | 3 (15.0) | |
| Treatment break required, n (%) | 2 (7.1) | 0 (0.0) | 0.504 |
| pCR rates, n (%) | 3 (16.7) | 3 (21.4) | 1 |
| pCR rates, microscopic, n (%) | 5 (27.8) | 8 (57.1) | 0.093 |
%, percentage of the total patients in each group.
a
Tumor grade unavailable for 1 patient with 3D-CRT; tumor size unavailable for 1 patient with IMRT.